Loading...
•
Dec 31, 2019
Evofem Biosciences Q4 2019 Earnings Report
Evofem Biosciences reported financial results for Q4 2019, with operating expenses decreasing and net loss per share improving compared to the prior year quarter. The FDA granted conditional approval for the brand name Phexxi.
Key Takeaways
Evofem Biosciences reported a decrease in total operating expenses and an improved net loss attributable to common stockholders for the fourth quarter of 2019. The company also announced the FDA granted conditional approval for the brand name Phexxi.
Total operating expenses decreased by 14% compared to the same quarter in the previous year.
Research and development costs decreased due to the completion of clinical trials.
General and administrative costs increased due to pre-commercialization activities and increased headcount.
Net loss attributable to common stockholders improved compared to the prior year quarter.
Evofem Biosciences
Evofem Biosciences
Forward Guidance
The company did not provide specific forward guidance in this earnings report. However, the report highlights the upcoming PDUFA date for Phexxi and the end-of-phase 2 meeting with the FDA for EVO100 as potential catalysts for future growth.
Positive Outlook
- Potential FDA approval of Phexxi
- Anticipated commercial launch of Phexxi
- Scheduled meeting with the FDA to discuss the AMPREVENCE trial results
- Potential clinical path for EVO100 for the prevention of urogenital acquisition of Chlamydia trachomatis
- Potential clinical path for EVO100 for the prevention of urogenital acquisition of Neisseria gonorrhea in women
Challenges Ahead
- Risks and uncertainties related to FDA approval of Phexxi
- Risks and uncertainties related to the commercial launch of Phexxi
- Risks and uncertainties related to the outcome of the scheduled meeting with the FDA
- Risks and uncertainties related to the clinical path for EVO100
- Important factors that could impair the value of Evofem Biosciences' assets and business